These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1472 related items for PubMed ID: 12006960

  • 1. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 3. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [Abstract] [Full Text] [Related]

  • 4. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 5. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 6. Diagnosis, treatment and outcome of Kawasaki disease in an Australian tertiary setting: a review of three years experience.
    Singh-Grewal D, Wong M, Isaacs D.
    J Paediatr Child Health; 2005 Feb; 41(9-10):495-9. PubMed ID: 16150066
    [Abstract] [Full Text] [Related]

  • 7. Corticosteroid treatment of refractory Kawasaki disease.
    Lang BA, Yeung RS, Oen KG, Malleson PN, Huber AM, Riley M, Ebbeson R, Ramsey SE, Laxer RM, Silverman ED, McCrindle BW, Ratnapalan S, Feldman BM.
    J Rheumatol; 2006 Apr; 33(4):803-9. PubMed ID: 16583481
    [Abstract] [Full Text] [Related]

  • 8. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 9. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 10. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
    [Abstract] [Full Text] [Related]

  • 11. [How does the time of diagnosis affect the course of disease in children with kawasaki syndrome? A retrospective analysis at one center].
    Raith W, Gamillscheg A, Heinzl B, Nagel BH, Koestenberger M, Beitzke A.
    Klin Padiatr; 2009 Nov 27; 221(2):83-8. PubMed ID: 19263328
    [Abstract] [Full Text] [Related]

  • 12. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
    Lee TJ, Kim KH, Chun JK, Kim DS.
    Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
    [Abstract] [Full Text] [Related]

  • 13. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
    Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C.
    Singapore Med J; 2006 Sep 31; 47(9):780-4. PubMed ID: 16924360
    [Abstract] [Full Text] [Related]

  • 14. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
    Pediatr Cardiol; 2003 Sep 31; 24(2):145-8. PubMed ID: 12457253
    [Abstract] [Full Text] [Related]

  • 15. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.
    J Pediatr; 2006 Jan 31; 148(1):38-43. PubMed ID: 16423595
    [Abstract] [Full Text] [Related]

  • 16. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
    Kubota M, Usami I, Yamakawa M, Tomita Y, Haruta T.
    J Paediatr Child Health; 2008 Jun 31; 44(6):359-62. PubMed ID: 18476929
    [Abstract] [Full Text] [Related]

  • 17. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC, Aronoff SC.
    Pediatrics; 2005 Oct 31; 116(4):989-95. PubMed ID: 16199713
    [Abstract] [Full Text] [Related]

  • 18. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
    Pediatrics; 2005 Dec 31; 116(6):e760-6. PubMed ID: 16322132
    [Abstract] [Full Text] [Related]

  • 19. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 31; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 20. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Wang CL, Wu YT, Lee CJ, Liu HC, Huang LT, Yang KD.
    J Pediatr; 2002 Oct 31; 141(4):560-5. PubMed ID: 12378198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.